Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2

Has Ly6G finally found a job?

In this issue of Blood, Wang et al reveal that ligation of Ly6G on murine neutrophils inhibits neutrophil recruitment, providing the first evidence of a function for this molecule.

M Current Mystery Messenger Revealed?

The identity of signaling elements that couple muscarinic acetylcholine receptor (mAChR) activation to M current (KCNQ K(+) channels) modulation has remained unknown despite decades of study. Suh and Hille (in this issue of Neuron) demonstrate that activation of phospholipase C (PLC) initiates M current modulation and that recovery requires ATP and phosphoinositide 4-kinase (PI 4-K). These data...

Has excimer coronary laser angioplasty finally found a niche?

Receptor–ligand binding: ‘catch’ bonds finally caught

Leukocyte recruitment to sites of inflammation is initiated by the selectin family of adhesion receptors. Recent research reveals that P-selectin binding to its ligand exhibits 'catch' to 'slip' bond transition that may help explain the shear threshold phenomenon.

A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2.

HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy.